Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Lifetime prevalence 7-13%. One of the most common anxiety disorders. Average age of onset is 13 years.
CBT (especially exposure-based), SSRIs/SNRIs, MAOIs (phenelzine), benzodiazepines (short-term). Response rates 50-65%.
MDMA enhances prosocial feelings, reduces social threat perception, and increases empathy -- directly targeting the core features of social anxiety. Psilocybin may reduce self-referential processing and social evaluative fears.
Danforth et al. (2018): MDMA-assisted therapy for social anxiety in autistic adults showed significant and lasting reductions.